-
Journal of the American Academy of... Dec 2016Tobacco exposure might be a modifiable risk factor for atopic dermatitis (AD). (Meta-Analysis)
Meta-Analysis Review
BACKGROUND
Tobacco exposure might be a modifiable risk factor for atopic dermatitis (AD).
OBJECTIVE
We examine the association between AD and exposure to tobacco smoke.
METHODS
We performed a systematic review and meta-analysis of observational studies (n = 86) in MEDLINE, EMBASE, Scopus, and Cochrane Library (1823-2015). Quality of evidence was assessed using the Newcastle-Ottawa Scale (NOS). A meta-analysis was performed using random-effects models to estimate pooled odds ratios (OR). Subset analyses were performed for different ages (children, adult), regions, study designs (cross-sectional, longitudinal), study sizes (<5000, ≥5000), study quality (NOS score <6, ≥6), and amount of smoking (mild, extensive).
RESULTS
A diagnosis of AD was associated with higher odds of active smoking (OR 1.87, 95% confidence interval 1.32-2.63) and exposure to passive smoke (OR 1.18, 95% confidence interval 1.01-1.38), but not maternal smoking during pregnancy (OR 1.06, 95% confidence interval 0.80-1.40). The association between active smoking and AD remained significant in children and adults, all continents studied, and study sizes, but all were cross-sectional designs and had NOS score 6 or greater. Passive smoke was associated with AD in children and adults, cross-sectional studies, South/Central American and African studies, study size less than 5000, and NOS score less than 6.
LIMITATIONS
AD severity and distribution were not assessed.
CONCLUSIONS
Active and passive exposure to smoke are associated with increased AD prevalence.
Topics: Africa; Age Factors; Asia; Central America; Cross-Sectional Studies; Dermatitis, Atopic; Europe; Female; Humans; North America; Pregnancy; Risk Factors; Smoking; South America; Tobacco Smoke Pollution
PubMed: 27542586
DOI: 10.1016/j.jaad.2016.07.017 -
PloS One 2023Atopic dermatitis (AD) is a common chronic inflammatory skin disease that affects adults worldwide. Recent evidence suggests that AD may be associated with cognitive... (Meta-Analysis)
Meta-Analysis
BACKGROUND
Atopic dermatitis (AD) is a common chronic inflammatory skin disease that affects adults worldwide. Recent evidence suggests that AD may be associated with cognitive dysfunction, but the results of individual studies have been inconsistent. This systematic review and meta-analysis aimed to evaluate the association between AD and cognitive dysfunction in middle-aged and older adults.
METHODS
To find relevant research, a comprehensive search of electronic databases from the beginning to March 2023 was carried out. Data were taken from studies that were eligible, and a meta-analysis was done to determine the pooled hazard ratio (HR) and 95% confidence interval (CI).
RESULTS
We searched three databases and found a total of 15 studied arms included in 5 cohort studies with over 8.5 million participants were included in the analysis. The results showed that individuals with AD had a higher risk of developing dementia of all-cause dementia (pooled hazard ratio (HR) = 1.16; 95% CI, 1.10-1.23,P<0.001) and the Alzheimer type (pooled HR = 1.28; 95% CI, 1.01-1.63,P<0.001) but not vascular dementia (pooled HR = 1.42; 95% CI, 0.99-2.04,P<0.001). Subgroup analyses showed that the association between atopic dermatitis and all-cause dementia was significant in Europe (P = 0.004) but not in Asia (P = 0.173) and was significant in prospective cohort studies (P<0.001) but not in non-prospective cohort studies (P = 0.068). Sensitivity analysis and publication bias detection confirmed the reliability of the overall findings.
CONCLUSIONS
In conclusion, this study demonstrated that AD was associated with increased risk of cognitive dysfunction, particularly dementia of the Alzheimer type and all-cause dementia, in middle-aged and older participants. Further research is needed to understand the mechanisms behind this association and its potential implications for clinical practice.
SYSTEMATIC REVIEW REGISTRATION
PROSPERO, identifier (CRD42023411627).
Topics: Middle Aged; Humans; Aged; Alzheimer Disease; Dermatitis, Atopic; Prospective Studies; Reproducibility of Results; Cognitive Dysfunction
PubMed: 37878635
DOI: 10.1371/journal.pone.0292987 -
Acta Dermatovenerologica Croatica : ADC 2014Several studies examined the relationship between birth weight and atopic diseases, but no consensus has yet been reached regarding the results. The purpose of this... (Meta-Analysis)
Meta-Analysis Review
Several studies examined the relationship between birth weight and atopic diseases, but no consensus has yet been reached regarding the results. The purpose of this paper was to perform a meta-analysis of the existing studies regarding the role of birth weight in the occurrence of atopic dermatitis. We carried out an extensive search in the international databases (Pubmed, Cochrane Library, and Web of Knowledge). We selected the cross-sectional, case-control, and cohort studies which analyzed the role of birth weight in the occurrence of atopic dermatitis. We performed a meta-analysis of the selected studies, and calculated the odds ratio (OR) and corresponding 95% confidence intervals (95% CI). We included 10 studies in the final meta-analysis, which comprised 110974 patients. Weight classification was in compliance with Pediatric Nutrition Surveillance System (PedNSS) Health Indicators. In the first meta-analysis, we selected patients with low weight (below 2500 g) and atopic dermatitis and compared them with those with normal weight (2500 - 4000 g) and atopic dermatitis. The analysis showed that low birth weight represents a protective factor in the occurrence of atopic dermatitis (OR = 0.68, CI: 0.63 - 0.75, P<0.0001). In the second meta-analysis, we compared patients with high weight (over 4000 g) and atopic dermatitis with those with normal weight and atopic dermatitis. The results indicated that increased birth weight represents a risk factor for atopic dermatitis (OR = 1.1; CI: 1.02 - 1.17; P = 0.01) Thus, low birth weight represents a protective factor for the occurrence of atopic dermatitis and high birth weight represents a risk factor for the occurrence of this disease.
Topics: Birth Weight; Dermatitis, Atopic; Disease Susceptibility; Humans; Infant, Low Birth Weight; Infant, Newborn; Infant, Premature; Risk Factors
PubMed: 25102793
DOI: No ID Found -
Pediatric Allergy and Immunology :... Nov 2020Allergic diseases are an increasing public health concern, and early life environment is critical to immune development. Maternal diet during pregnancy has been linked... (Meta-Analysis)
Meta-Analysis
RATIONALE
Allergic diseases are an increasing public health concern, and early life environment is critical to immune development. Maternal diet during pregnancy has been linked to offspring allergy risk. In turn, maternal diet is a potentially modifiable factor, which could be targeted as an allergy prevention strategy. In this systematic review, we focused on non-allergen-specific modifying factors of the maternal diet in pregnancy on allergy outcomes in their offspring.
METHODS
We undertook a systematic review of studies investigating the association between maternal diet during pregnancy and allergic outcomes (asthma/wheeze, hay fever/allergic rhinitis/seasonal allergies, eczema/atopic dermatitis (AD), food allergies, and allergic sensitization) in offspring. Studies evaluating the effect of food allergen intake were excluded. We searched three bibliographic databases (MEDLINE, EMBASE, and Web of Science) through February 26, 2019. Evidence was critically appraised using modified versions of the Cochrane Collaboration Risk of Bias tool for intervention trials and the National Institute for Clinical Excellence methodological checklist for cohort and case-control studies and meta-analysis performed from RCTs.
RESULTS
We identified 95 papers: 17 RCTs and 78 observational (case-control, cross-sectional, and cohort) studies. Observational studies varied in design and dietary intakes and often had contradictory findings. Based on our meta-analysis, RCTs showed that vitamin D supplementation (OR: 0.72; 95% CI: 0.56-0.92) is associated with a reduced risk of wheeze/asthma. A positive trend for omega-3 fatty acids was observed for asthma/wheeze, but this did not reach statistical significance (OR: 0.70; 95% CI: 0.45-1.08). Omega-3 supplementation was also associated with a non-significant decreased risk of allergic rhinitis (OR: 0.76; 95% CI: 0.56-1.04). Neither vitamin D nor omega-3 fatty acids were associated with an altered risk of AD or food allergy.
CONCLUSIONS
Prenatal supplementation with vitamin D may have beneficial effects for prevention of asthma. Additional nutritional factors seem to be required for modulating the risk of skin and gastrointestinal outcomes. We found no consistent evidence regarding other dietary factors, perhaps due to differences in study design and host features that were not considered. While confirmatory studies are required, there is also a need for performing RCTs beyond single nutrients/foods.
Topics: Asthma; Cross-Sectional Studies; Dermatitis, Atopic; Diet; Female; Food Hypersensitivity; Humans; Pregnancy
PubMed: 32524677
DOI: 10.1111/pai.13303 -
Frontiers in Immunology 2022Several clinical trials have evaluated the efficacy and safety of interleukin-13 (IL-13) with lebrikizumab and tralokinumab in patients with moderate to severe atopic... (Meta-Analysis)
Meta-Analysis
BACKGROUND
Several clinical trials have evaluated the efficacy and safety of interleukin-13 (IL-13) with lebrikizumab and tralokinumab in patients with moderate to severe atopic dermatitis (AD). However, the safety and efficacy of IL-13 inhibitors as a potent biologic for AD remain elusive.
OBJECTIVE
To assess the efficacy and safety of IL-13 inhibitors in moderate to severe AD.
METHOD
Randomized clinical trials (RCTs), comparing IL-13 inhibitors vs placebo treatment in patients with moderate to severe AD, were identified from public database from its inception to November 9, 2021. The study was registered in PROSPERO (CRD42021254920).
RESULTS
Six studies reporting 7 RCTs involving 2946 patients with moderate-to-severe AD were included for the pooled analysis. Compared with placebo, antagonizing IL-13 with lebrikizumab and tralokinumab showed a greater improvement in percentage change of EASI (MD -20.37, 95%CI -32.28, -8.47), and a larger proportion of patients achieving numerical rating scale (NRS) with more than 4-points improvement (RR 1.59, 95%CI 1.23, 2.05). Additionally, IL-13 inhibitors also improved impaired dermatology life quality index (DLQI) (MD -14.49, 95%CI -19.23, -9.75). In terms of safety, both lebrikizumab and tralokinumab were well tolerated, with the except that they were linked to an increased risk of conjunctivitis compared to placebo treatment.
CONCLUSION
Antagonizing IL-13 with lebrikizumab and tralokinumab have demonstrated encouraging clinical efficacy against moderate-to-severe AD with excellent safety profile, albeit they did come with a higher risk of conjunctivitis than placebo treatment.
SYSTEMATIC REVIEW REGISTRATION
https://www.crd.york.ac.uk/prospero/, identifier ID=CRD42021254920.
Topics: Conjunctivitis; Dermatitis, Atopic; Humans; Interleukin Inhibitors; Interleukin-13; Treatment Outcome
PubMed: 35967348
DOI: 10.3389/fimmu.2022.923362 -
American Journal of Clinical Dermatology Oct 2015Atopic dermatitis (AD) is an allergic disorder caused by both immunological dysregulation and epidermal barrier defect. Several studies have investigated the association... (Review)
Review
BACKGROUND
Atopic dermatitis (AD) is an allergic disorder caused by both immunological dysregulation and epidermal barrier defect. Several studies have investigated the association between AD and mental health disorders. Autism spectrum disorders (ASD) are a heterogeneous group of neurodevelopmental conditions characterized by impairments in social communication and restricted, stereotyped interests and behaviors. The concurrent increased prevalence of AD and ASD in the last decades has led many scientists to investigate the relationship between the two diseases.
OBJECTIVE
The aim of this systematic review was to examine the association between AD and ASD.
METHODS
A systematic review was performed according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. PubMed and ScienceDirect were searched up to March 2015 for all reports examining the association between ASD and AD. Descriptive statistics of the studies are reported.
RESULTS
The review included 18 studies assessing the association between ASD and AD. Of these studies, two focused on ASD in relation to AD alone, 14 discussed ASD in relation to both AD and other atopic disorders, and two evaluated AD in parents of children with ASD. Most of these studies found a positive association between the two disorders, although there were some studies going in the opposite direction. The entity of the association is somewhat inconsistent among the different studies given that the frequencies of AD in ASD compared with a control group ranged from 7 to 64.2%. In addition, odds ratios (ORs) or hazard ratios (HRs) gave different results as three studies found a weak association with an OR below 2 and a nonsignificant p value, and three other studies found a moderate or strong association with an OR ranging from 1.52 to 7.17 and a significant p value. When all atopic disorders were considered when evaluating the risk of ASD, the association was strong with an HR of 3.4 or an OR of 1.24 and p < 0.001.
CONCLUSIONS
Overall, the results of this systematic review seem to reveal an association between ASD and AD, suggesting that subjects with ASD have an increased risk of presenting with AD compared with typically developing controls, and vice versa. This association is supported by clinical/epidemiological aspects, shared genetic background and common immunological and autoimmune processes. However, the variability in study population and design, and the presence of other risk factors acting as confounding factors, sometimes contribute to inconsistent results. Further studies are needed to clarify the underlying pathophysiologic mechanism explaining the association between ASD and AD and to explore the causal association between the two conditions.
Topics: Asthma; Autism Spectrum Disorder; Conjunctivitis, Allergic; Dermatitis, Atopic; Food Hypersensitivity; Humans; Prevalence; Rhinitis, Allergic
PubMed: 26254000
DOI: 10.1007/s40257-015-0145-5 -
Journal of the American Academy of... Jul 2017It is unclear whether patients with atopic dermatitis (AD) have an altered prevalence or risk for contact sensitization. Increased exposure to chemicals in topical... (Meta-Analysis)
Meta-Analysis Review
BACKGROUND
It is unclear whether patients with atopic dermatitis (AD) have an altered prevalence or risk for contact sensitization. Increased exposure to chemicals in topical products together with impaired skin barrier function suggest a higher risk, whereas the immune profile suggests a lower risk.
OBJECTIVE
To perform a systematic review and meta-analysis of the association between AD and contact sensitization.
METHODS
The PubMed/Medline, Embase, and Cochrane databases were searched for articles that reported on contact sensitization in individuals with and without AD.
RESULTS
The literature search yielded 10,083 citations; 417 were selected based on title and abstract screening and 74 met inclusion criteria. In a pooled analysis, no significant difference in contact sensitization between AD and controls was evident (random effects model odds ratio [OR] = 0.891; 95% confidence interval [CI] = 0.771-1.03). There was a positive correlation in studies that compared AD patients with individuals from the general population (OR 1.50, 95% CI 1.23-1.93) but an inverse association when comparing with referred populations (OR 0.753, 95% CI 0.63-0.90).
LIMITATIONS
Included studies used different tools to diagnose AD and did not always provide information on current or past disease. Patch test allergens varied between studies.
CONCLUSION
No overall relationship between AD and contact sensitization was found. We recommend that clinicians consider patch testing AD patients when allergic contact dermatitis is suspected.
Topics: Dermatitis, Atopic; Dermatitis, Contact; Humans
PubMed: 28392290
DOI: 10.1016/j.jaad.2017.02.001 -
European Journal of Clinical... Dec 2022Janus kinase (JAK) inhibitors have been developed to treat moderate to severe atopic dermatitis, but there is little evidence comparing the safety profile of these... (Meta-Analysis)
Meta-Analysis
PURPOSE
Janus kinase (JAK) inhibitors have been developed to treat moderate to severe atopic dermatitis, but there is little evidence comparing the safety profile of these drugs. The aim of this study is to compare the relative safety of the different systemic JAK inhibitors in atopic dermatitis.
METHODS
Medline, EMBASE, and clinicaltrials.gov were searched to identify phase 2/3, clinical trials (RCTs) designed to evaluate the efficacy and safety of systemic JAK inhibitors in atopic dermatitis. Outcomes were the risk of any adverse event (AE), serious AEs, AEs leading to treatment discontinuation, any infection, serious infections, herpes zoster infection, and any cardiac or vascular event.
RESULTS
Eighteen RCTs were included. Compared with placebo, baricitinib (odds ratio [OR] 1.25, 95% credible interval [CrI] 1.03-1.55), abrocitinib (OR 1.54, 95% CrI 1.25-1.90), and upadacitinib (OR 1.46, 95% CrI 1.19-1.81) increase the risk of any adverse event. Abrocitinib (OR 1.62, 95% CrI 1.7-2.72), upadacitinib (OR 1.67, 95% CrI 1.19-2.43), and dupilumab (OR 1.69, 95% CrI 1.02-2.79) increase the risk of infections when compared with placebo. Dupilumab has a reduced risk of herpes zoster infection when compared with upadacitinib (OR 0.23; 95% CrI 0.08-0.81) No further statistically significant risk differences between treatments were identified.
CONCLUSIONS
The results suggest systemic JAK inhibitors for atopic dermatitis have a similar safety profile. However, as current data present limitations, postmarketing safety evidence will be crucial to draw definitive conclusions regarding the safety of JAK inhibitors.
Topics: Humans; Janus Kinase Inhibitors; Dermatitis, Atopic; Network Meta-Analysis; Herpes Zoster; Treatment Outcome; Severity of Illness Index
PubMed: 36207461
DOI: 10.1007/s00228-022-03400-4 -
American Journal of Clinical Dermatology Apr 2018Current systemic treatments for atopic dermatitis (AD) offer limited efficacy and are often restricted by safety concerns. Biologics may address the unmet need for... (Meta-Analysis)
Meta-Analysis Review
BACKGROUND
Current systemic treatments for atopic dermatitis (AD) offer limited efficacy and are often restricted by safety concerns. Biologics may address the unmet need for improved AD therapeutics.
OBJECTIVE
The aim of this study was to evaluate the efficacy and safety of biologic agents in AD.
METHODS
A systematic review and meta-analysis of studies evaluating AD patients treated with biologics was performed. The primary outcome was the Eczema Area and Severity Index (EASI)-75 response, while secondary outcomes were SCOring Atopic Dermatitis (SCORAD)-75, EASI-50, SCORAD-50, Investigator Global Assessment 0/1 responses, change in responses from baseline, and adverse events.
RESULTS
We included 13 randomized controlled trials (RCTs) and 10 observational studies evaluating nine biologics. High-quality evidence was available for dupilumab, nemolizumab and ustekinumab. Pooling five studies, at weeks 12-16 dupilumab 300 mg every week to every 2 weeks achieved EASI-75 responses of 55%, superior to placebo [relative risk (RR) 3.3, 95% confidence interval (CI) 2.9-3.6]. Nemolizumab had similar EASI-75 responses as placebo, but significantly improved pruritus. In online reports, lebrikizumab demonstrated superior EASI-50 responses versus placebo (RR 1.3, 95% CI 1.04-1.7), while tralokinumab had superior SCORAD-50 responses versus placebo, with borderline significance (RR 1.7, 95% CI 0.97-3.1). In two RCTs each, omalizumab and ustekinumab were comparable with placebo, while antithymic stromal lymphopoietin receptor, infliximab, and rituximab lacked adequate evidence of efficacy. All medications had a comparable safety profile to placebo.
LIMITATIONS
Lack of RCTs and the use of variable outcome measures limited conclusions.
CONCLUSION
Dupilumab is currently the only biologic with robust evidence of efficacy in AD. Nemolizumab, lebrikizumab, and tralokinumab show promise but further data are needed. Longer follow-up and larger studies will establish their safety profile.
Topics: Antibodies, Monoclonal; Biological Products; Dermatitis, Atopic; Dermatologic Agents; Humans; Observational Studies as Topic; Pruritus; Randomized Controlled Trials as Topic; Treatment Outcome
PubMed: 29098604
DOI: 10.1007/s40257-017-0324-7 -
Journal of the European Academy of... Jun 2019Zinc plays a central role in skin integrity via barrier and immune mechanisms and may also be relevant in the pathogenesis of atopic dermatitis (AD). However, little is... (Meta-Analysis)
Meta-Analysis
Zinc plays a central role in skin integrity via barrier and immune mechanisms and may also be relevant in the pathogenesis of atopic dermatitis (AD). However, little is known about the relationship between zinc and AD. We performed a systematic review to determine (i) the association between zinc levels or zinc deficiency and AD and (ii) the efficacy of oral zinc supplementation in the treatment of AD. We searched PubMed, Scopus, Web of Science and article references for observational studies on zinc levels or zinc deficiency in participants with AD vs. controls and for randomized control trials (RCTs) on zinc supplementation in AD. For observational studies, we calculated pooled standardized mean differences (SMDs) or odds ratios (ORs) along with 95% confidence intervals (CIs) using a random effects model. We included 14 observational studies and two RCTs. The pooled SMD demonstrated significantly lower serum (SMD 0.66, 95% CI 0.21-1.10, P = 0.004), hair (SMD 0.95, 95% CI 0.38-1.52, P = 0.001) and erythrocyte (SMD 0.95, 95% CI 0.38-1.52, P = 0.001) zinc levels in participants with AD compared to controls. Pooled unadjusted data from three studies showed a non-significant increased odds of AD in those with zinc deficiency compared with those without zinc deficiency (OR = 1.50, 95% CI 0.71-3.16, P = 0.28). One RCT of oral zinc supplementation among AD patients with zinc deficiency showed improvement in extent and severity of AD, while another RCT among all AD patients showed no significant improvement. All the studies were of low or moderate quality. We conclude that low serum, hair and erythrocyte zinc levels are associated with AD. However, the poor quality of included studies makes interpretation of these results problematic. High-quality observational studies are needed to confirm the association between low zinc levels and AD, and RCTs are required to evaluate the merit of zinc supplementation for the treatment or prevention of AD.
Topics: Deficiency Diseases; Dermatitis, Atopic; Dietary Supplements; Humans; Randomized Controlled Trials as Topic; Zinc
PubMed: 30801794
DOI: 10.1111/jdv.15524